Client of a consultant lobbyist
Novartis Pharmaceuticals Canada Inc.
- Meetings this Parliament
- 4
- With MPs
- 0
- Since Nov 2021
- 4
- Active registrations
- 1
Most recent reported meeting: Apr 29, 2026.
Lobbying by Novartis Pharmaceuticals Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since May 11, 2026
Consultant Cyrus Reporter of Gowling WLG
Consultant lobbyists
-
Cyrus Reporter
Former designated public office holder
Formerly Senior Advisor, Government of Canada, Office of the Prime Minister (2015–2017)
Formerly Chief of Staff to Minister of Industry, Minister's Office, Industry Canada (2002–2003)
Formerly Chief of Staff to the Minister of Health, Minister's Office, Health Canada (1997–2002)
Formerly Chief of Staff to the Minister of Justice and Attorney General for Canada, Minister's Office, Department of Justice (1997–1997)
-
Cyrus Reporter
Former designated public office holder
Formerly Senior Advisor, Government of Canada, Office of the Prime Minister (2015–2017)
Formerly Chief of Staff to Minister of Industry, Minister's Office, Industry Canada (2002–2003)
Formerly Chief of Staff to the Minister of Health, Minister's Office, Health Canada (1997–2002)
Formerly Chief of Staff to the Minister of Justice and Attorney General for Canada, Minister's Office, Department of Justice (1997–1997)
Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Prime Minister's Office (PMO), Privy Council Office (PCO)
What they're lobbying on (8)Hide details
- Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
- Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
- R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
- Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
- Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.
- Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
- Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
- Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Registration 776203-381968-2. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Cyrus Reporter · Consultant
- Niloo Boroun · Director of International Policy, Finance Canada (FIN)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Cyrus Reporter · Consultant
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Cyrus Reporter · Consultant
- Matthew Trnkus · Policy Advisor, Global Affairs Canada (GAC)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
-
Reported by Cyrus Reporter · Consultant
- Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
- Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.